The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.
NEW YORK (
sports five-year dividend growth of nearly 10% as well as a 3.5%+ annualized yield.
has a P/E of 9, a 5.3% dividend yield and three-year earnings growth of 19%. Meanwhile,
has a mammoth 35% trailing return on equity with a 5.8% annual dividend payout.
How in the world are investors overlooking the pharma space? Actually, the smart money hasn't overlooked it. The
iShares DJ Pharmaceuticals Fund
is part of a select group of stock ETFs with a price above a 200-day moving average. In fact, not many stock ETFs in that select group can lay claim to year-to-date gains of about 8%.
There are four pharmaceutical ETFs for those intrigued by a value-driven uptrend. Each tends to capitalize on slightly different aspects of the drug universe. For example,
SPDR S&P Pharma
maintains an equal weight strategy across 30 companies, which may lead to a greater focus on growth from the "anti Johnson & Johnsons." It follows that the yield is less compelling, but the potential for capital appreciation may be much greater.
The aforementioned IHE is relatively similar to XPH; both are less yield-oriented than pharma stocks are known for. That said, IHE is 1/4 less volatile than the S&P 500 whereas XPH is only a "skosh" less volatile than the U.S. benchmark.
In complete contrast, the
is dominated by Johnson & Jonhson
with a 25% allocation. With only a handful of the largest brand name constituents moving PPH's needle -- Merck, Eli Lilly, Pfizer, etc. -- the yield is more compelling (approx 3%), but the growth prospects are less so.
PowerShares Dynamic Pharmaceuticals Fund
rounds out the field. Its tracking of a
proprietary Intellidex Index
has led to superior bull market performance. Here are the 4 choices since the March 9, 2009 lows:
Perhaps ironically, three of the Pharma ETF choices don't provide enough dividend yield, making the investor rely almost entirely on capital appreciation in bull market uptrends. The other, PPH, is so wrapped up in JNJ, one can't escape the company's decade-long underachievement.
It follows that there may be a sweeter way to get your cake (yield) and eat it too (capital appreciation). Consider a fifth option -- the
Shares High Dividend Equity Fund (HDV). You
get 27% exposure to "Big Pharma" as well as a 30-day, annualized SEC yield of 4%. And, HDV has done a fine job picking up "cap app" to boot.